A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

Prior to deciding on a shared European vaccine supply purchase, the European Medicines Agency has begun analyzing the Danish firm’s smallpox vaccine against monkeypox.

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

In coming years, Novo Nordisk will take blows in the shape of several patents terminating on the second-biggest market for the firm, a Danish media reports.

Bavarian Nordic’s smallpox vaccine, Jynneos, hasn’t yet been approved for monkeypox in Europe, a fact that hasn’t stopped countries there from lining up to secure vaccine supplies in light of the recent outbreak.